AKT1 and pancreatic neoplasm: Finally, we have demonstrated for the first time the effectiveness of MM-121, a specific anti-ErbB3 inhibitor, to inhibit proliferation of PDAC cells as well as murine pancreatic cancer xenografts and to disrupt the activation of PI3K/AKT as a critical proliferative pathway.